Cargando…

Does Surgical Margin Width Remain a Challenge for Triple-Negative Breast Cancer? A Retrospective Analysis

Background and Objectives: Local and distant relapse (LR, DR) in breast cancer vary according to its molecular subtypes, with triple-negative breast cancer (TNBC) being the most aggressive. The surgical resection margin width (SRMW) for breast-conserving surgery (BCS) has been intensely debated, esp...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonci, Eduard-Alexandru, Țîțu, Ștefan, Petrușan, Alexandru Marius, Hossu, Claudiu, Gâta, Vlad Alexandru, Ghomi, Morvarid Talaeian, Kubelac, Paul Milan, Bonci, Teodora Irina, Piciu, Andra, Cosnarovici, Maria, Hîțu, Liviu, Kirsch-Mangu, Alexandra Timea, Pop, Diana Cristina, Lisencu, Ioan Cosmin, Achimaș-Cadariu, Patriciu, Piciu, Doina, Schmidt, Hank, Fetica, Bogdan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996718/
https://www.ncbi.nlm.nih.gov/pubmed/33652670
http://dx.doi.org/10.3390/medicina57030203
Descripción
Sumario:Background and Objectives: Local and distant relapse (LR, DR) in breast cancer vary according to its molecular subtypes, with triple-negative breast cancer (TNBC) being the most aggressive. The surgical resection margin width (SRMW) for breast-conserving surgery (BCS) has been intensely debated, especially for the aforementioned subtype. The aim of this study was to examine the impact of SRMW on LR following BCS in TNBC patients. Materials and Methods: We conducted a retrospective study including all patients with TNBC for whom BCS was performed between 2005 and 2014. Results: Final analysis included a total of 92 patients, with a median tumor size of 2.5 cm (range 0–5 cm) and no distant metastasis at the time of diagnosis. A total of 87 patients had received neoadjuvant and/or adjuvant chemotherapy, and all patients had received adjuvant whole-breast radiotherapy. After a median follow-up of 110.7 months (95% CI, 95.23–126.166), there were 5 local recurrences and 8 regional/distant recurrences with an overall LR rate of 5.4%. The risk of LR and DR was similar between groups of patients with several SRMW cut-off values. Conclusions: Our study supports a safe “no ink on tumor” approach for TNBC patients treated with BCS.